在集中式药房制剂单元中复用细胞抑制剂。
Reusing cytostatics in a centralised pharmacy preparation unit.
作者信息
Ramos Linares S, Merino Alonso J, Román González N, Tévar Alfonso E, Díaz Ruíz P, Gorchs Molist M
机构信息
Servicio de Farmacia, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, España.
出版信息
Farm Hosp. 2011 Mar-Apr;35(2):70-4. doi: 10.1016/j.farma.2009.12.012. Epub 2010 Dec 24.
OBJECTIVE
To measure and provide an economic assessment of the preparations returned to a centralised cytostatic drug preparation unit, analyse reasons for their return, propose measures for minimising returns and assess their impact on the Medical Oncology division's outpatient services.
METHODS
This prospective study contained two phases. During the first, we registered all returns, motives, cases of reuse and costs. In the second phase, we analysed returns at the Oncology outpatient division after having adopted measures to minimise the returns.
RESULTS
During the first phase, 218 preparations (worth € 51,131) were returned. The Oncology Day Hospital returned 1% of the preparations worth 1% of the total value; during the second phase, these figures were 0.56% of the preparations and 0.14% of the total value.
CONCLUSIONS
Favouring reporting on and identifying expensive treatments with little stability and using returned preparations as a quality indicator for Oncology has improved management of the central cystostatic preparation unit.
目的
对退回集中化细胞毒性药物配制单元的制剂进行计量并提供经济评估，分析其退回原因，提出减少退回的措施，并评估这些措施对肿瘤内科门诊服务的影响。
方法
这项前瞻性研究包括两个阶段。在第一阶段，我们记录了所有退回情况、退回动机、再利用案例和成本。在第二阶段，我们在采取措施减少退回后，对肿瘤门诊的退回情况进行了分析。
结果
在第一阶段，有218份制剂（价值51,131欧元）被退回。肿瘤日间医院退回的制剂占制剂总数的1%，价值占总价值的1%；在第二阶段，这些数字分别为制剂总数的0.56%和总价值的0.14%。
结论
鼓励报告并识别稳定性差的昂贵治疗方法，并将退回的制剂用作肿瘤学质量指标，已改善了中央细胞毒性制剂单元的管理。
Zotero 插件